Megan McClafferty, NP
Family · Nashville, TNNPI 1225776784
Payments from drug & device makers
Across 337 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$988
- Novo Nordisk$605
- Xeris Pharmaceuticals, Inc.$578
- Insulet Corporation$558
- Amgen$488
- AstraZeneca$438
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,049100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 48 | $988 |
| Novo Nordisk | 37 | $605 |
| Xeris Pharmaceuticals, Inc. | 31 | $578 |
| Insulet Corporation | 20 | $558 |
| Amgen | 30 | $488 |
| AstraZeneca(2 entities) | 23 | $438 |
| Mannkind Corporation | 16 | $363 |
| BETA Bionics, Inc. | 9 | $272 |
| Boehringer Ingelheim | 13 | $255 |
| Bayer | 12 | $250 |
| Cequr Corporation | 3 | $211 |
| AbbVie | 9 | $200 |
| Sanofi-aventis U.S. LLC | 11 | $200 |
| Novartis | 5 | $195 |
| Medtronic | 7 | $156 |
| IBSA Pharma Inc. | 6 | $117 |
| Radius Health, Inc. | 6 | $116 |
| Madrigal Pharmaceuticals | 3 | $96 |
| Recordati_rare_diseases_inc. | 4 | $82 |
| Intra-sana Laboratories | 3 | $80 |
| Corcept Therapeutics | 3 | $77 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| Ascensia Diabetes Care US Inc. | 3 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Ascendis Pharma Endocrinology Inc | 4 | $68 |
| Antares Pharma, Inc. | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $59 |
| Dexcom, Inc. | 2 | $48 |
| Sequel Med Tech, LLC | 2 | $46 |
| Tolmar, Inc. | 3 | $46 |
| Rhythm Pharmaceuticals, Inc. | 2 | $35 |
| Amphastar Pharmaceuticals, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,049 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $192,432 |
| TrulicityDulaglutide | 113 | $135,571 |
| MounjaroTirzepatide | 100 | $108,013 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 95 | $67,522 |
| JardianceEmpagliflozin | 71 | $61,142 |
| FarxigaDapagliflozin Propanediol | 74 | $56,797 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $46,469 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $35,626 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $29,379 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $25,097 |
| Novolog FlexpenInsulin Aspart | 60 | $15,961 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $15,562 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $13,287 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $11,119 |
| TradjentaLinagliptin | 15 | $10,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $988 | $244,717232 claims |
| Novo NordiskOzempic | $605 | $192,432159 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $255 | $87,084100 claims |
| AstraZenecaFarxiga | $438 | $56,79774 claims |
| Sanofi-aventis U.S. LLCLantus | $200 | $4,36222 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $59 | $2,462263 claims |
| AbbVieSynthroid | $200 | $2,44323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.